Citius Pharma to Attend EF Hutton and H.C. Wainwright Investor Conferences

Citius Pharmaceuticals, Inc. ("Citius"), a prominent biopharmaceutical company specializing in the development and commercialization of pioneering critical care products, has announced its participation in two significant upcoming investor conferences. These conferences are the EF Hutton Annual Global Conference on May 15, 2024, and the H.C. Wainwright BioConnect Investor Conference on May 20, 2024. Leonard Mazur, Chairman and CEO of Citius, will represent the company, holding one-on-one investor meetings at both events and giving a presentation at the H.C. Wainwright conference.

Citius Pharmaceuticals is focused on advancing its diverse pipeline of late-stage product candidates. Notably, the company recently completed enrollment for a Phase 3 pivotal superiority trial of Mino-Lok®, an innovative antibiotic lock solution designed to salvage catheters in patients who suffer from catheter-related bloodstream infections. This marks a significant milestone as the company moves closer to potentially providing a much-needed solution for such infections.

Additionally, the Biologics License Application for another of Citius's groundbreaking products, LYMPHIR™—an IL-2R immunotherapy targeted for initial use in treating cutaneous T-cell lymphoma (CTCL)—is under review by the FDA. The FDA has set August 13, 2024, as the target action date for this application. LYMPHIR has already received orphan drug designation from the FDA for treating both cutaneous and peripheral T-cell lymphoma (PTCL), highlighting its potential importance in oncology.

In a strategic move, Citius has also announced plans to form Citius Oncology, a separate publicly traded entity with LYMPHIR™ as its primary asset. This initiative underscores the company's commitment to advancing specialized therapies in oncology and maximizing the potential of LYMPHIR™ through dedicated focus and resources.

Furthermore, Citius has completed the enrollment for its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation aimed at providing relief for patients suffering from hemorrhoids. This development indicates the company’s broad approach in addressing various critical care needs through innovative therapeutic solutions.

These advancements reflect Citius Pharmaceuticals' dedication to addressing unmet medical needs through the development of first-in-class products. With a strong pipeline and strategic initiatives like the formation of Citius Oncology, the company continues to position itself as a key player in the biopharmaceutical industry, particularly in the areas of critical care and oncology.

By participating in these upcoming investor conferences, Citius aims to engage directly with potential investors, providing updates on their progress and future plans. Leonard Mazur’s participation in one-on-one meetings and presentations will offer valuable insights into the company's strategic direction and its ongoing efforts to bring advanced treatment options to market.

Citius Pharmaceuticals' proactive engagement in these conferences demonstrates its commitment to transparency and investor communication, ensuring that stakeholders are informed about the company's developments and strategic initiatives. This approach not only reinforces investor confidence but also highlights the potential impact of Citius's innovative therapies on addressing critical healthcare challenges.